The Anemia of Chronic Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Anemia of Chronic Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anemia of Chronic Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anemia of Chronic Disease and features dormant and discontinued products.
GlobalData tracks five drugs in development for Anemia of Chronic Disease by four companies/universities/institutes. The top development phase for Anemia of Chronic Disease is preclinical with four drugs in that stage. The Anemia of Chronic Disease pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Anemia of Chronic Disease pipeline products market are: Disc Medicine, Epitracker and Sumitomo Dainippon Pharma Oncology.
The key targets in the Anemia of Chronic Disease pipeline products market include Hemojuvelin (Hemochromatosis Type 2 Protein or RGM Domain Family Member C or HFE2), Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30), and TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30).
The key mechanisms of action in the Anemia of Chronic Disease pipeline product include Hemojuvelin (Hemochromatosis Type 2 Protein or RGM Domain Family Member C or HFE2) Inhibitor with three drugs in Phase I. The Anemia of Chronic Disease pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Anemia of Chronic Disease pipeline products market including Monoclonal Antibody, and Small Molecule.
Anemia of Chronic Disease overview
Anemia of chronic disease (ACD) or anemia of inflammation is a type of anemia that affects people who have conditions that cause inflammation, such as infections, cancer, autoimmune diseases, and chronic kidney disease (CKD). In ACD there is reduced iron levels in the blood. Symptoms includes fast heartbeat, body aches, fainting or feeling dizzy or light-headed, feeling tired or weak, getting tired easily during or after physical activity, pale skin, and shortness of breath. Complete blood count and blood smear can be used for diagnosis. Erythropoiesis-stimulating agents (ESAs) like epoetin alpha or darbepoetin alpha are used to treat anemia related to CKD, chemotherapy treatments for cancer, or certain treatments for HIV. Blood transfusions may be used in severe anemia.
For a complete picture of Anemia of Chronic Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
